AAPL   381.57 (-0.30%)
FB   242.26 (-0.92%)
GOOGL   1,523.89 (+0.34%)
AMZN   3,185.79 (+0.10%)
NVDA   419.54 (-0.20%)
CGC   16.96 (+5.87%)
BABA   260.52 (-0.41%)
MU   50.26 (+0.56%)
GE   6.67 (+1.37%)
TSLA   1,491.68 (+6.99%)
AMD   56.17 (-1.90%)
T   29.93 (+1.32%)
F   6.07 (+3.76%)
GILD   76.21 (+2.01%)
BAC   23.90 (+4.96%)
NFLX   553.61 (+9.03%)
BA   177.70 (+2.55%)
AAPL   381.57 (-0.30%)
FB   242.26 (-0.92%)
GOOGL   1,523.89 (+0.34%)
AMZN   3,185.79 (+0.10%)
NVDA   419.54 (-0.20%)
CGC   16.96 (+5.87%)
BABA   260.52 (-0.41%)
MU   50.26 (+0.56%)
GE   6.67 (+1.37%)
TSLA   1,491.68 (+6.99%)
AMD   56.17 (-1.90%)
T   29.93 (+1.32%)
F   6.07 (+3.76%)
GILD   76.21 (+2.01%)
BAC   23.90 (+4.96%)
NFLX   553.61 (+9.03%)
BA   177.70 (+2.55%)
AAPL   381.57 (-0.30%)
FB   242.26 (-0.92%)
GOOGL   1,523.89 (+0.34%)
AMZN   3,185.79 (+0.10%)
NVDA   419.54 (-0.20%)
CGC   16.96 (+5.87%)
BABA   260.52 (-0.41%)
MU   50.26 (+0.56%)
GE   6.67 (+1.37%)
TSLA   1,491.68 (+6.99%)
AMD   56.17 (-1.90%)
T   29.93 (+1.32%)
F   6.07 (+3.76%)
GILD   76.21 (+2.01%)
BAC   23.90 (+4.96%)
NFLX   553.61 (+9.03%)
BA   177.70 (+2.55%)
AAPL   381.57 (-0.30%)
FB   242.26 (-0.92%)
GOOGL   1,523.89 (+0.34%)
AMZN   3,185.79 (+0.10%)
NVDA   419.54 (-0.20%)
CGC   16.96 (+5.87%)
BABA   260.52 (-0.41%)
MU   50.26 (+0.56%)
GE   6.67 (+1.37%)
TSLA   1,491.68 (+6.99%)
AMD   56.17 (-1.90%)
T   29.93 (+1.32%)
F   6.07 (+3.76%)
GILD   76.21 (+2.01%)
BAC   23.90 (+4.96%)
NFLX   553.61 (+9.03%)
BA   177.70 (+2.55%)
Log in

NASDAQ:GENEGenetic Technologies Stock Price, Forecast & News

$2.37
-0.04 (-1.66 %)
(As of 07/10/2020 02:02 PM ET)
Add
Compare
Today's Range
$2.33
Now: $2.37
$2.45
50-Day Range
$2.01
MA: $2.19
$2.49
52-Week Range
$1.41
Now: $2.37
$5.36
Volume5,598 shs
Average Volume1.27 million shs
Market Capitalization$20.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.54
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GENE
CUSIPN/A
Phone011-61-3-8412-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Book Value$0.26 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$20.19 million
Next Earnings Date9/4/2020 (Estimated)
OptionableOptionable

Receive GENE News and Ratings via Email

Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.

Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions

How has Genetic Technologies' stock been impacted by COVID-19 (Coronavirus)?

Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GENE stock has increased by 0.4% and is now trading at $2.37. View which stocks have been most impacted by Coronavirus.

When is Genetic Technologies' next earnings date?

Genetic Technologies is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for Genetic Technologies.

Has Genetic Technologies been receiving favorable news coverage?

Headlines about GENE stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Genetic Technologies earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Genetic Technologies.

Who are some of Genetic Technologies' key competitors?

What other stocks do shareholders of Genetic Technologies own?

Who are Genetic Technologies' key executives?

Genetic Technologies' management team includes the following people:
  • Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)
  • Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. Director
  • Mr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec.

What is Genetic Technologies' stock symbol?

Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE."

How do I buy shares of Genetic Technologies?

Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genetic Technologies' stock price today?

One share of GENE stock can currently be purchased for approximately $2.37.

How big of a company is Genetic Technologies?

Genetic Technologies has a market capitalization of $20.19 million and generates $20,000.00 in revenue each year.

What is Genetic Technologies' official website?

The official website for Genetic Technologies is www.gtgcorporate.com.

How can I contact Genetic Technologies?

Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 011-61-3-8412-7000 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.